Gene Logic

[wolfes]

Hallo zusammen

sollte man jetzt zugreifen? Nach Aussagen von Analysten und meinen Bankmenschen, ja!

mfg

[DrMed]

<IMG SRC="http://www.marketguide.com/mgi/chart.asp?rt=chart&rn=A1731" border=0>

auf dem aktuellen Niveau sehe ich kein Risiko mehr. Rein mit der Knete.

DrMed

[HSnoopy]

Ich kann noch keine Kursrakete ausmachen. Der Chart zeigt eindeutig immer noch abwärts.
Ein Boden ist noch nicht zu erkennen.

Zudem hat Incyte Klage gegen Gene-Logic eingereicht. Das wirkt sich manchmal doch auf den Kurs aus.
http://www.juchu.de/ubb/Forum13/HTML/000110.html

Ich würde im Moment noch nicht kaufen.

[Michael G.]

HI zusammen,

eigentlich würde ich auch noch eine eindeutige Bodenbildung abwarten, denn solange diese nicht vollzogen ist, ist der Abwärtstrend voll intakt.

Ich glaube, dass es im Moment interessantere Alternativen gibt. Aber nichts desto trotz sollte man den Wert auf alle Fälle sehr genau verfolgen, denn es kann auch sehr schnell wieder in die andere Richtung gehen.

Schöne Grüße
Michael

[wolfes]

Hallo an alle,

sieht ja sehr gut aus werden schnell die 40$
sehen, oder?

mfg

[Luke]

Hallo Michael,

wie sieht deine Analyse jetzt aus?
Sind doch jetzt genau an der 38 Tgae Linie, ist jetzt der Punkt erreicht, mal mit einer kleinen Position einzusteigen??

Danke

[Michael G.]

Hi Luke,

aber nur, wenn Du auch wirklich mutig bist. Der heutige Rückschlag von beinahe 9 % in USA macht das Chartbild nicht gerade schöner und bringt die Bodenbildung doch wieder ein wenig in Gefahr. Ich persönlich würde ich hier eher noch zuwarten.

Schöne Grüße
Michael


P.S.: Oder unterschätze ich Deinen Mut ? http://www.juchu.de/ubb/wink.gif

[wolfes]

hallo

der chart sieht ja wirklich nicht mehr so berauschend aus wie vor 3 tagen aber man sollte denoch nicht vergessen das glgc einer der führenden b2b-provider von bio-und gentechnologischen informationen für die globale pharma-, biotech und lebensversicherungs-industrie ist! michael g.gebe dir recht das es wirklich ein sehr spekuativer kauf ist aber no risk no fun!

mfg

[wolfes]

Servus zusammen,

wow das ist doch was!

REMEMBER!!WHY THIS STOCK!$142


IT'S PURE GENE LOGIC
By Dr. Cynthia Miller, MD, Ph.D.

We are living in an exciting era. Never before has there been such great
anticipation on how greatly technological advancements will improve our
lives. And as the recent months indicate, this will be no different in
biotechnology. Many biotechnology and pharmaceutical companies have
embarked on quests to conquer diseases that many scientists and physicians
only dreamed of undertaking as recently as a couple of years ago.

One such company that perfectly represents this excitement in
biotechnology is Gene Logic (GLGC, $142). Gene Logic lies at the
epicenter of the growing biotechnology boom. Indeed, much of the hoopla
generated thus far in the popular press has focused on the near-completion
of our human genome sequence, but the big question is what will we do with
all this information? We must make sense of it. Gene Logic will provide
that bridge between human sequence and the drugs of tomorrow.

As the sequencing of the human genome nears completion, the products Gene
Logic has to offer will become that more powerful. And what exactly are
these tools? They are invaluable mega-databases that contain, among other
things, data on gene expression, protein structure, and information about
subtle characteristic differences between you and me in our DNA that may
be important for making tailor-made drugs some day. Pharmaceutical
companies will need the tools and services that GLGC has to offer so they
can determine -- with a quicker turn-around time -- if the drugs in
development are going after the right targets. One can already imagine
how important their products will become for the smaller pharmaceuticals
with more limited resources, since many of these companies can ill-afford
to design drugs that fail.

For example, let's say Pfizer is interested in developing a Drug X to
fight colon cancer. They want Drug X to block a particular pathway
component (e.g. an enzyme or other protein) believed to cause colon
cancer. Pfizer designs and synthesizes their candidate drug and tests it.
By using Gene Logic's GeneExpress databases, the R&D team at Pfizer knows
which set of genes are hyperactive in colon cancer. However, although
Drug X succeeds in blocking their target protein of interest, they realize
that the same subset of genes believed to be responsible for colon cancer
are STILL hyperactive. That is, Drug X has failed to induce a more global
anti-cancer effect. (Fact: a number of genes -- some known, some unknown
-- often go haywire before one develops cancer. Gene Logic's product can
help determine what those genes are). Therefore, Drug X fails. Pfizer
quickly goes on to candidate Y for testing. Time saved = money well not
spent. Cost efficiency helps increase profit margins.

Gene Logic is investing in a science that is known to work. The firm is
already producing proprietary products that are being used by major drug
companies and research institutions today. Analysts have projected the
company to become profitable by 2001. The company has also firmly
established itself as the industry leader. All one has to do is refer to
its client list, which includes Pfizer, Procter & Gamble, Schering-Plough,
SmithKline Beecham, Merck & Co. and PE Biosystems -- in short, a growing
list of the Who's-Who in pharmaceuticals. By also working closely with
Affymetrix (AFFX), the makers of the high-powered DNA array chips that
they use, Gene Logic will remain the dominant player for many years to
come.

Cynthia Miller, MD
cmiller128@hotmail.com

Dr. Cynthia Miller is a gastroenterologist by training and studies the
transcriptional responses in response to inflammation in macrophages. In
lay terms, she researches what anti-inflammatory genes are turned on and
when.

mfg

[wolfes]

nun alle festhalten!

Article for Gene Logic Inc (NASDAQ NM:GLGC)
6:01 AM

most recent headlines
next article:


Gene Logic Signs UCB Pharma to GeneExpress(TM) Subscription And Announces Expansion of
Custom Discovery Partnership


MONDAY, OCTOBER 02, 2000 6:01 AM
- PRNewswire

GAITHERSBURG, Md. and CAMBRIDGE, Mass., Oct 2, 2000 /PRNewswire via COMTEX/ -- Gene Logic Inc. (Nasdaq:GLGC), a leading
provider of genomic information, and UCB Research, a division of UCB Pharma, a global pharmaceutical company with headquarters in
Brussels, Belgium, announced today that UCB has subscribed to a segment of Gene Logic's GeneExpress(TM) Suite of databases for use
in UCB's drug discovery and development programs and they have expanded their current custom discovery partnership regarding
development of a custom gene expression database for new drug discovery focused on allergy. Financial terms of the multi-year
subscription and the expanded custom partnership were not disclosed.

Under the terms of the GeneExpress subscription, UCB will gain access to a subset of the GeneExpress Suite, specifically the Atlas
DataSuite. The GeneExpress Atlas DataSuite is an interactive information suite containing gene expression profiles of a broad survey of
normal human tissue, enabling researchers to quickly access normal gene expression levels across a broad selection of relevant human
organs and tissues. UCB Pharma becomes the first major pharmaceutical company to subscribe to the Atlas DataSuite, which Gene Logic
launched in August 2000. The agreement provides for broad deployment of the Atlas DataSuite and its related software tools across UCB
Pharma's global pharmaceutical research and development infrastructure.

Also under terms of the agreement, Gene Logic will construct a separate, custom database incorporating UCB's proprietary genomic data
which will allow UCB researchers to readily cross-reference this proprietary data with the nonproprietary data available in the GeneExpress
Atlas DataSuite.

Under the expanded custom partnership regarding allergic disease gene discovery, Gene Logic will use its patented READS(TM)
technology and Affymetrix Inc.'s (Nasdaq:AFFX) GeneChip(R) technology to identify genes that are differentially regulated in mast cells and
other cells central to allergic disease. Gene Logic will continue to apply this multiple platform approach for purposes of providing UCB novel
drug targets. In addition, the partnership affords Gene Logic the opportunity to gain rights to certain data generated from these studies for
eventual inclusion into the GeneExpress Suite.

"We look forward to another productive year of target discovery research with our collaborators at Gene Logic," said Dr. Tom Beck, UCB
Global Director of R&D. "The tools offered by Gene Logic together with our proprietary mast cell technology, have permitted a significant
leap in our understanding of this key allergic cell. The next stage of this research promises to take us to a higher level of defining disease
mechanisms in asthma and other allergic disorders in which the mast cell plays a central pathological role."

"We are thrilled that UCB Pharma, a current custom partner of ours, has not only expanded its existing agreement, but, more importantly,
has chosen to subscribe to one of our GeneExpress DataSuites," said David S. Murray, Senior Vice President, Marketing and Sales of
Gene Logic. "This multifaceted agreement incorporating both a partnership and subscription component is one of the cornerstones of our
vision of Gene Logic's business model going forward. Clearly, we have established ourselves as an invaluable resource for the entire
research group at UCB."

UCB Pharma Overview

UCB Pharma is a global leader in the research, manufacture and marketing of innovative therapeutics for allergy, respiratory and central
nervous system disorders. These products include Zyrtec(R) (cetirizine HCl), a leading antihistamine, and Keppra(R) (levetiracetam), a
novel anti-epileptic drug marketed in the U.S. and Europe by UCB. UCB Group is a world scale company based in Brussels, Belgium, which
is active in the pharma, chemical and film sectors. UCB's research activities seek to promote health, well being and quality of life. The
company currently employs over 9,000 people worldwide, of which 700 are dedicated to advancing UCB's pharmaceutical research and
development efforts. UCB Research, Inc., based in Cambridge, Ma., is a division of UCB Pharma.

For more information, visit the company's Web site at http://www.ucb- group.com.

Gene Logic Overview

Gene Logic Inc. is a leading provider of genomic information, enabling the discovery and development of pharmaceutical, biotechnology,
health care, and life science products through the systematic and industrialized application of genomics and bioinformatics. Gene Logic has
built and is commercializing the world's most comprehensive survey of gene expression in human and animal tissues. Gene expression,
which is the degree to which genes in a cell are switched on or off, or regulated, is information critical to understanding the functions of
genes. Gene Logic markets two types of gene expression database products to the global pharmaceutical, biotechnology, health care and
life science industries: its custom databases and related software products and the GeneExpress Suite of databases. The GeneExpress
Suite can be used to discover and validate novel drug targets, develop and prioritize therapeutic compounds and facilitate clinical trials and
patient management. Today, thirteen companies use Gene Logic's various gene expression products for drug discovery, predictive
toxicology, diagnostic applications, and the identification of genes for agricultural applications.

For more information about Gene Logic, visit the company's Web site at http://www.genelogic.com or telephone toll-free on
1-800-GENELOGIC.

All statements in this press release that are not historical are considered forward-looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, including statements regarding Gene Logic's "expectations," "beliefs," "goals," "hopes,"
"strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Gene
Logic from those projected, including, but not limited to, risks and uncertainties relating to technological approaches, product development,
production, market acceptance, cost and pricing of Gene Logic products, utility of genomic information in drug discovery and development,
dependence on collaborative partners, sole source suppliers, competition, customer renewals and terminations, intellectual property of
Gene Logic and others, and patent protection and litigation. These and other risk factors are discussed in Gene Logic's Annual Report on
Form 10-K for the year ended December 31, 1999 and Gene Logic's other SEC reports, including its Quarterly Reports on Form 10-Q for
subsequent quarterly periods.

SOURCE Gene Logic Inc.

[wolfes]

Hallo zusammen,

kann mir einer die daten von den QZ von
0,29 bestätigen! wäre ja super

mfg

[wolfes]

Gene Logic Reports Third Quarter 2000 Results -- Revenues Increased 25% over Prior Year's Third Quarter --


GAITHERSBURG, Md.--(BW HealthWire)--Oct. 30, 2000--Gene Logic Inc. (Nasdaq: GLGC), a leading provider of genomic
information products, today announced its results for the third quarter of 2000.

Revenues for the three months ended September 30, 2000 were $5.3 million, a 25% increase over the $4.2 million reported for
the comparable period of 1999. Revenues for the nine months ended September 30, 2000 were $16.8 million, a 25% increase
over the $13.5 million reported for the comparable period of 1999. This increase resulted from increased revenues for
subscriptions to the Company's GeneExpressTM Suite of databases.

For the three months ended September 30, 2000, the Company reported a net loss of $8.0 million, or $0.31 per share, compared
to a net loss of $5.4 million, or $0.27 per share, for the same period in 1999. The net loss for the first nine months of 2000 was
$18.0 million, or $0.72 per share, compared to $14.7 million, or $0.74 per share, for the same period in 1999.

Operating expenses for the three months ended September 30, 2000 were $17.1 million, compared to $9.7 million for the
comparable period of 1999. Operating expenses for the nine months ended September 30, 2000 were $44.9 million, compared to
$28.7 million for the comparable period of 1999. The increase in operating expenses was attributable to the continuing expansion
of database content and infrastructure, including increased sales and marketing efforts, necessary to support existing and
planned growth of the GeneExpressTM Suite of products.

As of September 30, 2000, Gene Logic had approximately $231.4 million in cash and cash equivalents.

"Through the first ten months of 2000, our closure rate of seven pharmaceutical and biotechnology company subscriptions to the
GeneExpressTM Suite continues to keep pace with our goal of ten customers by the end of the year," commented Philip L.
Rohrer, Jr., Chief Financial Officer of Gene Logic. "During the third quarter, the continued investments in our sales and marketing
efforts began to pay off. For the remainder of 2000 and into 2001 we look to continue to aggressively sign new users to the
GeneExpressTM Suite as its extraordinary value and utility as a genomics information tool becomes more widely known, expand
the breadth and depth of the content and functionality of the GeneExpressTM Suite, and sign additional strategic partnership
opportunities where prudent."

Third Quarter / Early Fourth Quarter 2000 Highlights

-- Product Development

Gene Logic completed the update of the content of the

GeneExpressTM Suite using the new Affymetrix, Inc. HU-95 Human

Genome GeneChip(R) set which includes 60,000 human genes and ESTs,

replacing the HU-35 Human Genome GeneChip(R) set which included

42,000 human genes and ESTs.

Gene Logic completed the latest upgrade to the GeneExpressTM 2000

software interface, expanding from version 1.1 to version 1.2, and

began introducing the new interface to all current GeneExpressTM

Suite subscribers.

-- Business Partnerships

Gene Logic announced a business development collaboration with

Amersham Pharmacia Biotech K.K. to market and sell Gene Logic's

entire line of genomic information products to the Japanese

pharmaceutical and biotechnology market.

-- Business Development

Gene Logic signed a two-tiered agreement with UCB Pharma

encompassing the expansion of an existing custom discovery

partnership for a custom gene expression database in the area of

allergy and asthma and a subscription to a CustomSuite of the

GeneExpressTM Suite including access to the Atlas DataSuite, a

subset focused on normal gene expression, and a separate yet

integrated custom database incorporating their proprietary data.

Investors may listen to Gene Logic's senior management discuss the details of this announcement during a conference call
scheduled for Monday, October 30, 2000 from 9:00 to 10:30 a.m. EST by dialing: domestic - 800/283-1693; or international -
703/736-7227 (NO PASSCODE). A replay of this call will be available through Monday, November 13, 2000 by dialing either of the
previously mentioned numbers. A webcast of the call will also be available for live participation accessed from the Company's
Web site - www.genelogic.com. (http://www.genelogic.com.) The webcast will be archived following the call for the next 90 days and is located at the
Company Web site - www.genelogic.com. (http://www.genelogic.com.)

Gene Logic Inc. Overview

Gene Logic Inc. is a leading provider of genomic information, enabling the discovery and development of pharmaceutical,
biotechnology, health care, and life science products through the systematic and industrialized application of genomics and
bioinformatics. Gene Logic has built and is commercializing the world's most comprehensive survey of gene expression in
human and animal tissues. Gene expression, which is the degree to which genes in a cell are switched on or off, or regulated, is
information critical to understanding the functions of genes. Gene Logic markets two types of gene expression database products
to the global pharmaceutical, biotechnology, health care and life science industries: its custom databases and related software
products and the GeneExpressTM Suite of databases. The GeneExpressTM Suite can be used to discover and validate novel
drug targets, develop and prioritize therapeutic compounds and facilitate clinical t ials and patient management. Today, a number
of pharmaceutical and biotechnology companies use Gene Logic's various gene expression products for drug discovery,
predictive toxicology and diagnostic applications. For more Information about Gene Logic, visit the company's Web site at
www.genelogic.com (http://www.genelogic.com) or telephone toll-free on 1-800-GENELOGIC. - more -

All statements in this press release that are not historical are considered forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Gene Logic's "expectations,"
"beliefs," "goals," "hopes," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Gene Logic from those projected, including, but not limited to, risks and uncertainties relating to
technological approaches, product development, production, market acceptance, cost and pricing of Gene Logic products, utility
of genomic information in drug discovery and development, dependence on collaborative partners, sole source suppliers,
competition, ability to sign new subscribers, customer renewals and terminations, intellectual property of Gene Logic and others,
and patent protection and litigation. These and other risk factors are discussed in Gene Logic's Annual Report on Form 10-K for
the year ended December 31, 1999 and Gene Logic's other SEC reports, including its Quarterly Reports on Form 10-Q. Gene
Logic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Gene Logic's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.

Financial tables follow.

GENE LOGIC INC.

Consolidated Condensed Statements of Operations

(In thousands, except per share amounts)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

------------------------ ---------------------

2000 1999 2000 1999

------------ ----------- ----------- ---------

Revenues $ 5,269 $ 4,223 $ 16,811 $ 13,502

Expenses:

Research and

development 11,955 7,020 31,049 21,506

Selling, general

and

administrative 4,731 2,335 12,662 6,094

Amortization

of goodwill 381 381 1,143 1,143

------------ ----------- ----------- ---------

Total expenses 17,067 9,736 44,854 28,743

------------ ----------- ----------- ---------

Loss from operations (11,798) (5,513) (28,043) (15,241)

Interest (income),

net (3,828) (126) (9,957) (589)

Other (income) -- -- (234) (30)

Income tax expense -- -- 160 100

------------ ----------- ----------- ---------

Net loss $ (7,970) $ (5,387) $ (18,012) $ (14,722)

------------ ----------- ----------- ---------

------------ ----------- ----------- ---------

Basic and Diluted

Net Loss Per Common

Share $ (0.31) $ (0.27) $ (0.72) $ (0.74)

------------ ----------- ----------- ---------

------------ ----------- ----------- ---------

Shares Used in

Computing Basic

and Diluted Net 25,798 19,887 24,939 19,799

Loss Per Common

Share

------------ ----------- ----------- ---------

------------ ----------- 5---------- ---------

GENE LOGIC INC.

Consolidated Condensed Balance Sheets

(In thousands)

September 30, December 31,

2000 1999

-------------------- ---------------

(unaudited)

ASSETS

Current assets:

Cash, cash equivalents

and marketable

securities

available-for-sale $ 231,419 $ 12,446

Due from collaborators 3,008 3,549

Inventory 1,530 1,735

Prepaid expenses 1,891 822

Other current assets 2,675 1,335

-------------------- --------------

Total current assets 240,523 19,887

Property and equipment, net 13,508 10,527

Long-term investments 9,081 1,000

Note receivable from employee 75 735

Goodwill, net 4,582 5,725

Intangibles and other assets,

net 8,197 3,292

-------------------- --------------

Total assets $ 275,966 $ 41,166

-------------------- --------------

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $ 4,378 $ 4,506

Accrued expenses 5,121 2,759

Current portion of

capital lease obligation -- 192

Current portion of

long-term debt 1,385 1,335

Deferred revenue 2,879 5,672

-------------------- --------------

Total current

liabilities U 13,763 14,464

Capital lease obligation -- 201

Deferred revenue 784 --

Long-term debt 1,921 2,862

Other noncurrent liabilities 610 571

-------------------- --------------

Total liabilities 17,078 18,098

-------------------- --------------

Stockholders' equity:

Common stock 259 200

Additional paid-in capital 355,840 103,497

Deferred compensation on

stock options, net (1,061) (2,488)

Accumulated other

comprehensive loss -- (3)

Accumulated deficit (96,150) (78,138)

-------------------- --------------

Total stockholders'

equity 258,888 23,068

-------------------- --------------

Total liabilities and

stockholders' equity $ 275,966 $ 41,166

-------------------- --------------

CONTACT:

Gene Logic Inc.

Robert Burrows, 301.987.1824

Director, Corporate Communications

email: rburrows@genelogic.com

or

Noonan Russo Communications, Inc.

Prateek Patnaik (media), 212.696.4455 Ext. 273

email: p.patnaik@noonanrusso.com

KEYWORD: MARYLAND

BW0033 OCT 30,2000

3:29 PACIFIC

6:29 EASTERN

[wolfes]

Article for Gene Logic Inc (NASDAQ NM:GLGC)
4:45 PM

most recent headlines
next article:


The AEA Classic Conference to be Broadcast by Investor Broadcast Network Over the Internet
- Part 8


FRIDAY, NOVEMBER 03, 2000 4:45 PM
- BusinessWire

PHILADELPHIA, Nov 3, 2000 (BUSINESS WIRE) -- The AEA Classic will be broadcast by Investor Broadcast Network
beginning Monday, November 6 at 11:00 AM Eastern and continuing through Friday, November 10.

This press release contains only a partial list of presenting companies. A complete list of presenting companies can
be found at http://www.vcall.com/NASApp/VCall/EventPage?ID=52465. Participating companies are subject to
change, so please check back often.

The following companies and speakers will be available for on-demand listening on Friday, November 10, 2000 at 8:00
AM Eastern:

-- Geoworks Corporation (NASDAQ: GWRX) executives at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52206

-- Digimarc Corporation (NASDAQ: DMRC) CFO E.K. Ranjit, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52204

-- Itron, Inc. (NASDAQ: ITRI) CEO LeRoy Nosbaum, and VP of IR,
Mima Scarpellui, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52208

-- Jacada Ltd. (NASDAQ: JCDA) President, Michael Potts, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52209

-- Gene Logic, Inc. (NASDAQ: GLGC) Director of Corporate
Communications, Robert Burrows, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52205

-- Applied Films Corporation (NASDAQ: AFCO) President and CEO,
Thomas Edman, and CFO, Lawrence Firestone, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52202

-- iManage, Inc. (NASDAQ: IMAN) President and CEO, Max Panjwani,
and CFO, Mark Culhane, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52207

-- Corillian Corporation (NASDAQ: CORI) CFO, Steve Sipowicz, and
EVP Corporate Development, Alex Hart, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52203

-- MSC.Software Corporation (NYSE: MNS) CEO and Chairman, Frank
Perna, at http://www.vcall.com/NASApp/VCall/EventPage?ID=52210

-- Prime Response, Inc. (NASDAQ: PRME) President and CEO, Peter
Boni, and CFO, Fred Phillips, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52211

This event is also available through Investor Broadcast Network's Vcall.com and InvestorConference.com websites,
located at http://www.vcall.com, and http://www.InvestorConference.com, respectively. Listeners should go to one
website at least fifteen minutes before these events to download and install any necessary audio software. For those
unable to attend the live broadcast, a replay will be available for 90 days unless otherwise requested by a participating
company. There is no charge to access any event.

About Investor Broadcast Network

Investor Broadcast Network is the leading broadcaster of real-time investment information and analysis on the Internet.
With a complete portfolio of web-based broadcast communication services, the company gives investors access to the
inner circle of corporate executives and industry thought leaders, while providing public companies with an efficient
online investor relations strategy that meets their financial needs and reduces the high-risk of selective disclosure. For
more information on Investor Broadcast Network visit www.investorbroadcast.com (http://www.investorbroadcast.com)

könnte einiges bringen! Leute stellt euch vor
wenn Gene Logic nur ein drug findet kann das
einen millionen umsatz bedeuten!
2 Großkunden sollen heuer noch an land gezogen werden!
GLGC ist auf eine Sicht von 12 Monaten afu mittlerweile 150-200$ zu sehen.


mfg

[biotech-pro.de]

Gene Logic Inc. konnte im ersten Quartal seinen Nettoverlust auf 7,5 Mio. Dollar oder 28 Cents je Aktie reduzieren, nach einem Vorjahresverlust von 10,6 Mio. Dollar oder 40 Cents je Aktie. Analysten hatten mit einem Verlust von 30 Cents gerechnet. Begründet wurde der Gewinnrückgang mit der steigenden Nachfrage von Pharma-Unternehmen nach der Datenbank mit genetischen Informationen. Damit wuchs der Umsatz von 8,2 Mio. Dollar im Vorjahresquartal auf 11,8 Mio. Dollar.

[Odo]

Gene Logic präsentiert für das zweite Quartal einen Verlust von 4.4 Millionen Dollar oder 16 cents je Aktie, nach 9.4 Millionen Dollar oder 35 cents je Aktie Verlust im Vorjahr. Das Ergebnis je Aktie liegt um 4 cents über den Schätzungen der Wall Street. Der Umsatz stieg in den vergangenen drei Monaten um 46 Prozent auf 14.1 Millionen Dollar.

Für das zweite Halbjahr warnt der Anbieter von Gen-Informationen und bioinformatischen Produkten vor einem langsameren Umsatzwachstum, da das Geschäft mit neuen Kunden zunehmend erlahmte und der Trend in Zukunft so weiter gehen wird, so die Erwartung des Unternehmens.

Das Unternehmen spricht in Folge eine Gewinnwarnung aus und prognostiziert für das dritte Quartal einen Verlust von 7.2 Millionen Dollar oder 27 cents je Aktie und für das vierte Quartal einen Verlust von 6 Millionen Dollar oder 22 cents je Aktie. Der Umsatz soll in den jeweiligen Zeiträumen bei 14.2 bzw. 15 Millionen Dollar liegen. Der gesamte Ausblick liegt unter den Schätzungen der Analysten.

[Odo]

Gene Logic steigen um 5.38% auf $6.66, nachdem der Anbieter von Geninformationsprodukten und -Dienstleistungen einen Vertrag unterzeichnete, der die Lieferung der GeneExpress Datenbank an Roche vorsieht. Finanzielle Details wurden nicht bekanntgegeben.

[Odo]

Gene Logic wird TherImmune für $52 Millionen in Aktien und Bargeld übernehmen. Dabei sollen $31 Millionen in Bar und $21 Millionen in neuen Aktien bezahlt werden. Das Biotechnologieunternehmen rechnet damit, dass die Transaktion im zweiten Quartal abgeschlossen sein und sich im Jahr 2003 positiv auf das Ergebnis auswirken wird. TherImmune soll Gene Logic helfen, seine Produkte und Dienstleistungen im Bereich Geninformationen zu stärken und zu verbessern.